Sandoz Issues Mid-term Outlook For 2025-2030; Unveils Bio100 Ambition

Sandoz reaffirmed its existing mid-term outlook through 2028 and introduced 2025-2030 targets for mid-to-high single-digit average annual net-sales growth at constant currencies. The company also set a core EBITDA-margin target beginning at 25%, though the article text is truncated before the full margin range is provided. The reaffirmed and extended targets signal confidence in sustained growth and profitability.